PMC:7321036 / 928-1244 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T21","span":{"begin":4,"end":16},"obj":"GO:0065007"},{"id":"T22","span":{"begin":48,"end":61},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T23","span":{"begin":80,"end":83},"obj":"PR:000008220"},{"id":"T24","span":{"begin":174,"end":182},"obj":"SP_7"},{"id":"T25","span":{"begin":259,"end":269},"obj":"SP_7"},{"id":"T77793","span":{"begin":4,"end":16},"obj":"GO:0065007"},{"id":"T44088","span":{"begin":48,"end":61},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T2452","span":{"begin":80,"end":83},"obj":"PR:000008220"},{"id":"T31032","span":{"begin":174,"end":182},"obj":"SP_7"},{"id":"T9784","span":{"begin":259,"end":269},"obj":"SP_7"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T85537","span":{"begin":279,"end":284},"obj":"Body_part"}],"attributes":[{"id":"A57709","pred":"fma_id","subj":"T85537","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":174,"end":182},"obj":"Disease"},{"id":"T14","span":{"begin":259,"end":267},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T20161","span":{"begin":279,"end":284},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T36852","span":{"begin":294,"end":303},"obj":"http://purl.obolibrary.org/obo/SO_0000418"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":131,"end":140},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T36282","span":{"begin":294,"end":303},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}

{"project":"LitCovid-PubTator","denotations":[{"id":"18","span":{"begin":80,"end":83},"obj":"Gene"},{"id":"19","span":{"begin":95,"end":98},"obj":"Gene"},{"id":"30","span":{"begin":174,"end":182},"obj":"Disease"},{"id":"33","span":{"begin":259,"end":278},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Gene:5594"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Gene:558"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":39,"end":193},"obj":"Sentence"},{"id":"T9","span":{"begin":195,"end":213},"obj":"Sentence"},{"id":"T10","span":{"begin":215,"end":225},"obj":"Sentence"},{"id":"T11","span":{"begin":226,"end":312},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis of SARS-CoV-2-infected cells uncovers signaling rewiring\n• "}